NEUMORA THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent
NEUMORA THERAPEUTICS, INC. (NMRA) reported Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent of -2.90% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate · last filed 2026-03-30
- NEUMORA THERAPEUTICS, INC. effective income tax rate reconciliation, change in enacted tax rate, percent for fiscal 2024 was -2.90%, a 180.56% decline from fiscal 2023.
- NEUMORA THERAPEUTICS, INC. effective income tax rate reconciliation, change in enacted tax rate, percent for fiscal 2023 was 3.60%.
| Period end | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent 12 month |
|---|---|
| 2024-12-31 | -2.90% 10-K · filed 2026-03-30 |
| 2023-12-31 | 3.60% 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |